Table 3.
Quality Assessment of the Selected Studies
| S.No | Criteria | Bad (0–33%) | Satisfactory (33–66%) | Good (67–100%) |
|---|---|---|---|---|
| 1 | The objective of this paper stated | – | – | 17 studies |
| 2 | Study population clearly specified | – | – | 17 studies |
| 3 | Participation rate of eligible persons at least 50% | – | – | 17 studies |
| 4 | Eligibility criteria | – | – | 17 studies |
| 5 | Sample size justification | – | – | 17 studies |
| 6 | miRNA Exposure assessed before outcome measurement | – | – | 17 studies |
| 7 | Timeframe sufficient for the patients (OS, DFS or MFS) | – | – | 17 Studies |
| 8 | Different levels of the exposure of interest (mode of treatment) | – | Six studies | 11 studies |
| 9 | Exposure measures and assessment (staging of cancer, TNM) | – | Three studies | 19 studies |
| 10 | Repeated exposure assessment | – | Seven studies | Ten studies |
| 11 | Outcome measures (HR, and CI) | – | One study | 16 studies |
| 12 | Blinding of outcome assessors | NA | NA | NA |
| 13 | Follow-up rate | – | Five studies | 12 studies |
| 14 | Statistical analysis | – | – | 22 studies |
| Total selected studies | 0 | 1 | 16 |